Popular
BlogNEW
CompaniesNEW
Finance
Technology
Banking
Information Technology
Oil and Energy
Internet
Mining and Metals
Communications
Real Estate
Biotechnology
Automotive
Medical
Retail
Energy
Investor Presentaiton slide image

Investor Presentaiton

Shield CRC performance is in range with other non-invasive guideline-recommended modalities INVESTOR 20 DAY 23 74-92% CRC sensitivity for current guideline-recommended tests 1,2 87-96% Specificity for current guideline-recommended tests 1,2 GUARDANT™ 1. Imperiale, et al. 2014. NEJM; 2 Knudsen, et al. 2021. JAMA 106
View entire presentation

Product

HomeSearchAccount

Categories

Finance PresentationsTechnology PresentationsBanking PresentationsInformation Technology PresentationsOil and Energy PresentationsInternet PresentationsMining and Metals PresentationsCommunications PresentationsReal Estate PresentationsBiotechnology PresentationsAutomotive PresentationsMedical PresentationsRetail PresentationsEnergy Presentations

Company

InsightsContactSupport

Legal

Terms of ServicePrivacy Policy

Connect

TwitterLinkedInInstagramYouTube